Company · HALO (NASDAQ - All Markets)
Halozyme Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Key figures
- Revenue, 2025
- $1.4B
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Institutional holders
- 668 at 30 Jun 2026 (636 the quarter before)
- SEC number
- 1159036
Source: SEC EDGAR filings and company facts, SEC Form 13F; checked 12 Oct 2026
With a free account
A free account opens 10 full pages a month and lets you follow this page: 12 quarters of figures, every filing and document, earnings call transcripts, holders and ownership changes, the Brain's cards and graph, exports to Excel.
Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.